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In this work, the role of HDAC6, a type II histone deacetylase with tubulin deacetylase activity, in lymphocyte polarity,
motility, and transmigration was explored. HDAC6 was localized at dynamic subcellular structures as leading lamelli-
podia and the uropod in migrating T-cells. However, HDAC6 activity did not appear to be involved in the polarity of
migrating lymphocytes. Overexpression of HDAC6 in freshly isolated lymphocytes and T-cell lines increased the
lymphocyte migration mediated by chemokines and their transendothelial migration under shear flow. Accordingly, the
knockdown of HDAC6 expression in T-cells diminished their chemotactic capability. Additional experiments with
HDAC6 inhibitors (trichostatin, tubacin), other structural related molecules (niltubacin, MAZ-1391), and HDAC6 dead
mutants showed that the deacetylase activity of HDAC6 was not involved in the modulatory effect of this molecule on cell
migration. Our results indicate that HDAC6 has an important role in the chemotaxis of T-lymphocytes, which is
independent of its tubulin deacetylase activity.
INTRODUCTION
Lymphocyte migration is essential for the activity of the
immune system in physiological conditions and during
adaptive immune responses. Lymphocyte chemotaxis re-
quires the coordinated activity of adhesion and chemotactic
receptors, signaling molecules, and cytoskeleton (Vicente-
Manzanares and Sanchez-Madrid, 2004). Chemokines are a
family of low-molecular-weight cytokines that bind to G
protein–coupled receptors on the cell surface (Mackay,
2001). In addition to their classical function as chemoattrac-
tants, chemokines modulate lymphocyte adhesion to endo-
thelium, through a yet-poorly understood mechanism of
receptor cross-talk between chemotactic and adhesion recep-
tors (Alon and Feigelson, 2002; von Andrian and Mackay,
2000). Chemokines also trigger the remodeling of cytoskel-
eton and the reorganization of multiple plasma membrane
receptors and signaling molecules, which result in an overall
change of lymphocyte shape and the acquisition of a migra-
tory, polarized morphology (Sanchez-Madrid and del Pozo,
1999). Lymphocyte polarization involves the generation of
two well-differentiated poles. The leading edge clusters actin
microfilaments, actin-associated proteins, and signaling
molecules that generate protrusive structures, and concen-
trates adhesion receptors at the cell front. On the other hand,
adhesions are released at the rear trailing edge to enable net cell
movement (Serrador et al., 1999; Worthylake and Burridge,
2001; Etienne-Manneville and Hall, 2002; Ridley et al., 2003;
Vicente-Manzanares and Sanchez-Madrid, 2004).
Although there is much knowledge on how the actin
cytoskeleton participates in cell migration (Pantaloni et al.,
2001; Pollard and Borisy, 2003), the role played by tubulin
and associated proteins in this process remains controversial
and seems cell type-dependent (Wittmann and Waterman-
Storer, 2001; Destaing et al., 2005). However, it is clear that,
in addition to their role during cell division, microtubules
play important functions in the establishment and mainte-
nance of cell polarity and adhesion (Prescott et al., 1989;
Tannenbaum and Slepecky, 1997; Moreno and Schatten,
2000; Small and Kaverina, 2003). The majority of interphase
microtubules are dynamic, but a small proportion is rela-
tively stable (Schulze and Kirschner, 1987), showing a low
rate of depolymerization by colchicine or cold. Microtubule
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stability is related to post-translational modifications of tu-
bulin subunits (Gundersen et al., 1998), including the acety-
lation of the Lys40 -amino group of -tubulin (L’Hernault
and Rosenbaum, 1983; Piperno and Fuller, 1985). This type
of acetylation has been found in a variety of proteins (tran-
scription and nuclear import factors, histones) and is cata-
lyzed by a wide range of acetyltransferases (Kouzarides,
2000; Polevoda and Sherman, 2002). In cultured cells, acet-
ylation seems to preferentially occur in polymerized micro-
tubules (Piperno et al., 1987). It has been shown that in vivo,
deacetylation takes place on tubulin dimers, rather than
microtubules (Matsuyama et al., 2002).
HDAC6, a class II histone deacetylase mainly localized in
the cytoplasm (Verdel et al., 2000; Bertos et al., 2004), has two
catalytic domains with deacetylase activity. The C-terminal
domain is able to deacetylate -tubulin both in vitro and in
vivo, and this activity is reversibly inhibited by trichostatin
A (TSA) and tubacin. TSA is a broad HDACs inhibitor,
whereas tubacin is specific for the tubulin deacetylase activ-
ity of HDAC6 (Hubbert et al., 2002; Matsuyama et al., 2002;
Haggarty et al., 2003; Zhang et al., 2003). These compounds
inhibit the HDAC6 deacetylase activity by chelating a Zn2
cation (Furumai et al., 2001; Jose et al., 2004) and may also
alter the formation of dynamic molecular complexes of
HDAC6 with other intracellular proteins such PP1, HSP90,
Dia2, dynein, or tubulin (Kawaguchi et al., 2003; Brush et al.,
2004; Destaing et al., 2005; Hideshima et al., 2005; Kovacs et
al., 2005). In this regard, it has been reported that TSA
disrupts HDAC6/PP1 association, affecting the enzymatic
activity of both molecules (Brush et al., 2004).
We have herein investigated the role of HDAC6 in the
migration of T-lymphocytes. We found that HDAC6 is
mainly concentrated at cellular regions with high protrusive
activity in migrating lymphocytes and that its expression
modulates lymphocyte chemotaxis independently of its en-
zymatic activity.
MATERIALS AND METHODS
Reagents and Antibodies
Trichostatin A (TSA), nocodazole (NCD), and paclitaxel (Taxol; TXL) were
purchased from Calbiochem (San Diego, CA). SDF-1 was from R&D Systems
(Minneapolis, MN), and sodium butyrate from Sigma Chemical Co. (St. Louis,
MO). Tubacin, DHM-tubacin, niltubacin, MAZ-1391, MAZ-1338, and MAZ-
1380 were synthesized according to Mazitschek et al. (unpublished data). The
80-kDa fibronectin fragment (FN80) was a generous gift from Dr. A. Garcı´a-
Pardo (Centro de Investigaciones Biolo´gicas, Madrid, Spain). Phytohemaglu-
tinin A (PHA) and interleukin-2 (IL-2) were from Sigma. Rabbit and goat
anti-human HDAC6 polyclonal antibodies were purchased from MBL
(Watertown, MA) and Santa Cruz Biotechnology (Santa Cruz, CA), respec-
tively. The anti--tubulin B-5–1-2 monoclonal antibody (mAb), the FITC-
conjugated anti--tubulin (clone DM1A), and the anti-acetylated -tubulin
6–11B-1 mAbs were purchased from Sigma. The JL-8 anti-GFP mAb was from
BD Biosciences Clontech (Palo Alto, CA). For surface molecule staining, the
following mAbs were used: HP2/19 anti-ICAM-3, 12G5 anti CXCR4, MAB181
anti-CCR5, PL-1 anti-PSGL-1, anti-CD62L, Lia3/2 anti-CD18, HP2/21 anti-
CD43 and HUTS-21 anti-activated 1 integrins.
Cells
Human T-cell lines HSB-2 and CEM 1.3 were grown in RPMI 1640 culture
medium (Invitrogen, Gaithersburg, MD) supplemented with 10% fetal calf
serum (FCS). Human peripheral blood lymphocytes (PBLs) were obtained as
described by Campanero et al. (1994), and T lymphoblasts by 48-h treatment
with 1 g/ml PHA, followed by 50 U/ml IL-2 in RPMI 1640 medium until the
eleventh day.
Transfection of Cells and Recombinant DNA Constructs
PBLs were washed once in phosphate-buffered saline and resuspended (1.2
107 cells/ml) in electroporation buffer containing 12 g of plasmid DNA
pEGFP, wtHDAC6-EGFP or double mutant HDAC6 H216A/H611A-EGFP
(HDAC6 DD). Cell suspensions (100 L) were transferred to a 2.0-mm elec-
Figure 1. Tubulin acetylation increases during T-
lymphocyte activation. (A) PBLs were incubated
with PHA (1 g/ml) for 48 h, washed, and cultured
in the presence of 50 U/ml IL-2. At indicated times,
cells were sonicated and cell lysates were subjected
to SDS-PAGE and immunoblot for detecting total
and acetylated tubulin, as stated in Materials and
Methods. The progressive increase in acetylated tu-
bulin during lymphocyte activation, and the values
of the acetylated/total tubulin ratio are shown. (B)
Double immunofluorescence staining for tubulin
(green fluorescence) and acetylated tubulin (red
fluorescence) in resting PBLs, T-lymphoblasts, and
HSB-2 T-cells. The predominant localization of
acetylated tubulin in bundles around MTOC is
shown.
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troporation cuvette and nucleofected with an Amaxa Nucleofector apparatus
(Amaxa GmbH, Cologne, Germany). Then, cells were transferred to complete
medium without antibiotic and cultured in six-well plates at 37°C until
analysis. HSB-2 cells were transfected by electroporation. The human T-cell
line CEM 1.3 was transduced with the retroviral vector pLZR IRES to stably
express EGFP, wtHDAC6-EGFP, or HDAC6 H216A/H611A-EGFP. Retrovi-
ruses were produced by transfection of the Phoenix packaging cell line with
a DNA mixture containing 2.5 g env (pVSV-G; Clontech, BD Biosciences), 4
g gag-pol (pNGVL3-MLV) and 3.5 g retroviral vector pLZR IRES (a gener-
ous gift from Dr. A. Bernad, Centro Nacional de Biotecnologı´a, Cantoblanco,
Madrid, Spain). Supernatant with retroviruses was recovered and filtered 48 h
after transfection and diluted 1:2 in RPMI 1640 medium. The infection was
carried out by spinning 5.0  105 CEM cells, with 200 l of retroviral
supernatant and polybrene at 6 g/ml, per well (24-well plates, Costar,
Corning, NY), at 1800 rpm, 30°C for 90 min. Finally, 300 l of complete RPMI
medium was added, and cells were cultured at 37°C in 5% CO2 atmosphere.
siRNA Assay
Double-stranded siRNA (21 pb) against the HDAC6 217–237 (Hubbert et al.,
2002; Serrador et al., 2004) and 284–304 sequences, and the negative control
was purchased from Eurogentec (Hampshire, United Kingdom). PBL cells
(7.0  106) were nucleofected with the siRNA using the Human T-Cell
nucleofector kit (Amaxa GmbH). Efficiency was assessed by Western blot.
Immunofluorescence Microscopy
These assays were performed as described (Serrador et al., 2004). Briefly, 5.0
105 cells were allowed to adhere to coverslips coated with FN80. When
indicated, cells were pretreated or not with SDF-1, TSA, TSASDF-1, NCD,
TXL, or sodium butyrate. Cells were then fixed and stained for acetylated and
total -tubulin using the 6-11B-1 and DM1A antibodies. Endogenous HDAC6
was stained with the goat anti-HDAC6 antibody and a secondary donkey
anti-goat Alexa-488–conjugated antibody. Cells were observed in a Leica
DMR photomicroscope (Leica, Mannheim, Germany), and images were visu-
alized, processed, and stored by using the Leica QFISH software.
Time-Lapse Fluorescence Confocal Microscopy
PBL or CEM cells (5  105) were allowed to adhere on FN-coated coverslips,
maintained in 1 ml of 2% BSA Hanks’ balanced salt solution (HBSS) on
Attofluor open chambers (Molecular Probes, Eugene, OR), and placed on the
microscope stage. Cells were maintained at 37°C in a 5% CO2 atmosphere.
Series of fluorescence and differential interference contrast frames were ob-
Figure 2. HDAC 6 and acetylated tubulin localization in motile T-lymphocytes. (A) Localization of endogenous HDAC6 and acetylated
tubulin in HSB-2 cells and PBLs. Cells adhered to FN-coated coverslips were fixed, permeabilized, and double-stained for HDAC6 and
acetylated tubulin. (B) HDAC6-Flag–transfected HSB-2 cells pretreated with the indicated drugs were adhered to FN-coated coverslips and
stained with antibody against acetylated tubulin and HDAC6-Flag, as stated in Materials and Methods. (C) HDAC6-GFP–transfected PBLs
incubated with the indicated stimuli and adhered to 50 g/ml FN were fixed, permeabilized, and stained for acetylated tubulin. Arrows
pointed to leading edge and the asterisk stands on the rear pole in the SDF-1–polarized PBLs. (D) Time-lapse sequence of HDAC6-GFP–
expressing PBLs transfected by nucleofection. Cells were allowed to adhere to FN and stimulated with 100 ng/ml SDF-1 at time zero. Then,
cells were analyzed for 7 min by time-lapse confocal microscopy, as stated in Materials and Methods. Arrows pointed to the leading edge in
the SDF-1–polarized migrating PBLs.
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tained simultaneously, using a Leica TCS SP confocal laser scanning unit
attached to a Leica DMIRBE inverted epifluorescence microscope.
Chemotaxis Assay in Transwell Chambers
Assays for lymphocyte chemotaxis were performed in nude or TNF-–acti-
vated human umbilical vein endothelial cells (HUVEC)-coated polycarbonate
membranes of 6.5-mm diameter, 10-m thickness, and 3- or 5-m-diameter
pore size Transwell chambers (Costar). Lymphocytes (100 l at 1.0  106
cells/ml) resuspended in 0.5% human serum albumin RPMI 1640 were added
to the upper chamber. Then, chemokines (100 ng/ml SDF-1) were added to
the lower chamber, and cells were allowed to migrate for 2 h at 37°C in 5%
CO2 atmosphere. Then, the migrated cells were recovered and counted by
flow cytometry.
Transendothelial Migration under Flow Conditions
The parallel plate flow chamber used for leukocyte adhesion and transmigra-
tion under defined laminar flow has been described (Barreiro et al., 2002). PBL
or CEM T-cells (106/ml) were drawn on a TNF-–activated confluent endo-
thelial monolayer at an estimated wall shear stress of 1.8 dyn/cm2 for a total
perfusion time of 10 min. Lymphocyte rolling on the endothelium was easily
visualized because they traveled more slowly than free-flowing cells. Lym-
phocytes were considered to be adherent after 20 s of stable contact with the
cell monolayer. Transmigrated lymphocytes were determined as being be-
neath the endothelial monolayer. Lymphocytes were considered detached
when they returned to free-flowing after their complete arrest on endothe-
lium. The number of rolling, adhered, transmigrated, and detached cells was
quantified by direct visualization of eight different fields (20 phase-contrast
objective) at each time point of every independent experiment.
For detachment experiments, PBLs untreated or pretreated with TSA or
sodium butyrate for 1 h were allowed to adhere for 4 min at 37°C to activated
HUVEC monolayers. Then, shear stress was applied by pulling assay buffer
(HBSS buffer with 2% FCS) through the flow chamber with a calibrated
programmable pump, starting at 0.5 dyn/cm2 and increasing up to 10 dyn/
cm2 at 1-min intervals. Attached and transmigrated cells after each shear
stress interval were quantified (20 phase-contrast objective), and the
mean  SD of seven fields is presented. Cell detachment was obtained from
the difference of final to initial adhered plus transmigrated cells (Barreiro et
al., 2005).
Western Blot Analysis
Cell lysates were subjected to 10% SDS-PAGE under reducing conditions, and
transferred onto nitrocellulose membranes (Trans-Blot, Bio-Rad, Hercules,
CA). Then, membranes were saturated with tris-buffered saline-0.1% Tween
containing 3% BSA and incubated with mAb against -tubulin or acetylated-
Figure 3. Effect of HDAC6 inhibitor TSA on PBL chemotaxis and adhesion. PBLs were incubated with the indicated drugs (1 mM butyrate,
10 nM TXL, 5 g/ml NCD, or 5 M TSA) and the following assays performed: (A) Chemotaxis assays in Transwell chambers. PBLs were
allowed to migrate toward 100 ng/ml SDF-1. The percentage of migrated cells  SD is shown. (B) Transmigration across TNF-–activated
endothelium in Transwell chambers. The percentage of migrated cells SD is shown. (C) Adhesion to fibronectin. The percentage of adhered
cells SD is shown. (D) Adhesion to resting (white bars) or TNF- activated (dark gray bars) endothelium. The percentage of adhered cells
SD is shown. (E) Lymphocyte transendothelial migration under physiological shear flow conditions across TNF-–activated HUVEC cells.
The number of rolling (white bars), adhered (light tone gray bars), transmigrating (dark gray bars), and detached (black bars) cells  SD is
shown and was calculated as described in Material and Methods. (F) TSA treatment augments PBL detachment under shear stress. The
percentage of detached cells was analyzed in seven different fields under increasing flow rates, ranging from 0.5 to 10 dyn/cm2 of wall shear
stress, and is represented as the mean  SD. (), control PBLs without treatment; f, 1 mM sodium butyrate; , 5 M TSA pretreatment,
1 h.
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-tubulin or HDAC6 or GFP, followed by a peroxidase-conjugated secondary
antibody. Proteins were visualized by enhanced chemiluminescence, and
densitometric analyses were performed with ImageGauge 3.46 software (Fuji
Photo Film Co., Tokyo, Japan).
Tubacin-niltubacin competition assays were carried out for 120 min at 37°C
and 5% CO2 in CEM leukemic T-cells and PBLs. Tubacin (0.25 or 0.5 M) was
coincubated with at least eight different concentrations, from 1 nM to10 M,
of niltubacin to determine IC50 (concentration [M] of this competing ligand
that inhibits by 50% the effect of tubacin binding). Western blotting of acety-
lated tubulin resulting from the competitive effect of niltubacin versus tubacin
for HDAC6 was then performed. Data were analyzed using GraphPad Prism
2.0 software (GraphPad Software, San Diego, CA).
RESULTS
HDAC6 Is Concentrated in Motile Structures of Polarized
Migrating Lymphocytes
To explore the role of HDAC6 in lymphocyte polarity, we
first determined the possible relationship between the levels
of acetylated tubulin and the polarized shape of T-cells. As
expected, we found an increase in total tubulin in PBLs
activated with PHA and cultured with IL-2 that peaked
between days 4 and 8 (Figure 1A, bottom panel). However,
the increase in the levels of acetylated tubulin reached max-
imal levels at day 8 of cell culture (Figure 1A, top, and B).
Acetylated microtubules were preferentially organized in
bundles around the microtubule-organizing center (MTOC)
within the cellular uropod (Figure 1B). Likewise, HSB-2 T-cells,
which exhibit a constitutively polarized morphology (Serrador
et al., 1997), also displayed significant amounts of acetylated
-tubulin concentrated at their uropods (Figure 1B).
We then assessed the subcellular localization of HDAC6
in polarized migrating lymphocytes. Immunofluorescence
experiments showed that HDAC6 was mainly concentrated
at the front lamellipodium of polarized cells and evenly
distributed in resting PBLs (Figure 2A). On the other hand,
in HSB-2 cells or PBLs transfected with either flag- or GFP-
tagged HDAC6, this enzyme was concentrated at the uro-
pod and the leading edge (Figure 2, B–D). This localization
was maintained when cells were treated with TSA or so-
dium butyrate, a HDACs inhibitor that lacks activity on
HDAC6 (Serrador et al., 2004).
The effect of HDAC6 overexpression on microtubule acety-
lation was also studied. Tubulin acetylation levels were re-
duced in cells overexpressing HDAC6 (Figure 2, B and C), an
effect that was inhibited by TSA (Figure 2, B and C). In TSA-
treated cells, HDAC6 colocalized with acetylated microtubules
(Figure 2, B and C). Chemokines have been reported as main
inducers of lymphocyte polarity (del Pozo et al., 1995). When
TSA-treated PBLs were induced to polarize with SDF-1,
they acquired a polarized migratory morphology, and HDAC6
was redistributed to the leading edge and the uropod (Figure 2,
C and D). Live-cell time-lapse confocal videomicroscopy con-
firmed the localization of HDAC6 at motility-associated struc-
tures in PBLs transfected with HDAC6-GFP and stimulated
with SDF-1 (Figure 2D and sal material, Supplementary
Video 1).
Lymphocyte Transmigration Inhibition by HDAC6
Inhibitor TSA
We then investigated the role of HDAC6 in lymphocyte
migration. Pretreatment of PBLs with TSA for 1 h (to avoid
its effect on gene transcription) decreased lymphocyte che-
motaxis and their transendothelial migration (Figure 3A,
and B). Similar results were observed in HSB-2 and CEM
T-cells (unpublished data). The inhibitory effect of TSA was
more evident when lymphocytes were allowed to transmigrate
across the endothelial cell monolayer. On the other hand, treat-
ment of lymphocytes with TXL decreased cell migration,
whereas NCD had an opposing effect (Figure 3B). Additional
experiments showed that TSA did not have a significant effect
on T-cell adhesion or the expression of chemokine and adhe-
sion receptors (Figure 3, C and D, and Table 1A).
The role of HDAC6 activity in T-cell migration was also
analyzed under flow conditions. Although butyrate did not
significantly affect any step of lymphocyte transendothelial
migration, TSA-treated cells showed a reduced adhesion to the
activated endothelium under shear stress, and the detachment
rate was significantly higher compared with untreated or bu-
tyrate-treated cells (Figure 3E). Furthermore, cell detachment
assays at increasing shear flow showed that the binding
strength of either untreated or butyrate-treated PBLs adhered
to activated endothelial cells was higher than that of TSA-
treated PBLs (Figure 3F). These findings indicate that TSA
negatively affects lymphocyte extravasation, mainly their firm
adhesion to endothelium under flow stress conditions, an effect
that is not evident under static conditions. This could be due to
blockage of deacetylase activity and/or disruption of HDAC6
molecular complexes by TSA (Brush et al., 2004).
Deacetylase Activity of HDAC6 Is Not Involved in
Lymphocyte Migration
To further explore the role of HDAC6 enzymatic activity in
lymphocyte migration, we used tubacin (a specific HDAC6
tubulin deacetylase inhibitor), and other deacetylase inac-
tive tubacin derivatives (niltubacin, MAZ-1391, MAZ-1338,
and MAZ-TBDPS-O-1380) (Figure 4, A and B). Tubacin in-
hibits HDAC6 tubulin deacetylase activity in a dose-depen-
dent manner, reaching a plateau at 10–20 M, whereas
niltubacin did not exert any effect at the same doses (Figure
4B and unpublished data). Tubacin inhibited the chemotaxis
Table 1. Effect of TSA, tubacin, and niltubacin on lymphocyte ad-
hesion and chemokine receptor expression
A
Molecule Control
TSA
(5 M)
CXCR4 640.41 631.03
CCR5 38.31 43.11
PSGL-1 313.93 321.39
CD62L 558.26 540.46
CD18 423.79 472.97
ICAM3 719.08 752.29
Activated 1 integrins 59.33 50.37
CD43 751.51 841.03
B
Molecule Control
Tubacin
(25 M)
Niltubacin
(25 M)
CXCR4 45.95 43.37 45.51
CCR5 4.17 4.81 3.78
PSGL1 18.25 18.51 12.75
CD18 12.33 10.27 11.01
ICAM3 31.89 30.79 26.77
Activated 1 integrins 5.46 5.68 4.58
CD43 96.01 130.48 87.95
(A) PBLs were treated or not with TSA for 1 h and analyzed by flow
cytometry (arbitrary units). (B) CEM cells were treated as indicated
over 6 h and then analyzed by flow cytometry (arbitrary units, Geo
Mean).
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of PBLs, HSB-2, and CEM T-cells induced by SDF-1 (Figure
4C and unpublished data). Unexpectedly, the inactive com-
pounds niltubacin, MAZ-1338, and MAZ-1391 also de-
creased cell migration (Figure 4C). In contrast, the inactive
derivative MAZ-TBDPS-O-1380 did not exert this effect (Fig-
ure 4C). Neither tubacin nor niltubacin affected the adhesion
of PBLs or T-cells to FN-80 in static conditions (Figure 4D).
Likewise, no significant changes on cell viability and the
expression levels of different adhesion and chemokine re-
ceptors were detected when CEM cells were treated with
tubacin or niltubacin (Table 1B and unpublished data).
To further ascertain whether niltubacin was exerting its
effects by binding to the same and/or overlapping site(s)
as tubacin on the HDAC6 molecule, cross-competitive
tubulin deacetylase functional assays were performed.
Niltubacin prevented the inhibitory effect of tubulin
deacetylase caused by tubacin, in a dose-dependent manner
(Figure 5, A–C), thus indicating both molecules were interact-
ing with the same and/or overlapping site(s) of the HDAC6
molecule. In parallel, migration assays showed that the com-
bination of tubacin (0.5 M) with increasing doses of niltuba-
cin, which revert the tubacin-deacetylase inhibitory effect,
resulted in a similar inhibition level of lymphocyte migra-
tion compared with same doses of tubacin alone (Figure 5D).
Therefore, although tubacin is an active specific inhibitor of
HDAC6 tubulin deacetylase, its effect on lymphocyte migra-
tion seems to be exerted independently of its inhibitory
effect upon deacetylase enzymatic activity. Moreover, in
Figure 4. Effects of specific HDAC6 inhibitor tubacin and derivatives on lymphocyte chemotaxis. (A) Molecular structure of Tubacin and
derivatives, where the Zn2 chelating group is marked. TSA formula is also included. (B) Western-blot showing the tubulin acetylation levels
in cells untreated or treated with 50 M of the indicated chemical inhibitors is shown. (C) Cell migration assays in Transwell chambers.
Dose-dependent inhibitory effects of HDAC6 targeting drugs on the chemotactic response of CEM T-cells to SDF-1. (D) Adhesion to FN (20
g/ml for T-cell lines and 50 g/ml for PBLs) of lymphocytes untreated or treated with Tubacin and niltubacin. Four representative
experiments are shown. Arbitrary units.
J. R. Cabrero et al.
Molecular Biology of the Cell3440
T-lymphocyte polarization induced by the chemokine SDF-
1, similar results were observed in cells treated with TSA,
tubacin or niltubacin, which suggest that HDAC6 tubulin
deacetylase activity is neither essential for lymphocyte po-
larization (Figures 2 and 6) nor migration (Figures 4C and 5).
Overexpression of HDAC6 and the Deacetylase Dead
Mutant Enhances T-Lymphocyte Migration
The effect of HDAC6 on lymphocyte migration was also
analyzed. CEM T-cells were transduced and PBLs were
nucleofected to overexpress wtHDAC6-GFP or HDAC6
H216A/H611A-GFP (Figure 7, A and B, and 8A, respec-
tively). We found that overexpression of wtHDAC6 or
deacetylase dead mutant in CEM leukemic T-cells (Figure
7B) and PBLs (Figure 8A) exhibited enhanced transmigra-
tion when compared with GFP-alone overexpressing cells.
Interestingly, migratory CEM cells overexpressing either
HDAC6-GFP or HDAC6 H216A/H611A-GFP showed an
accumulation of this enzyme at the cell leading edge and, in
lesser extent, in the uropod (Figure 7C, Supplementary Vid-
eos 2 and 3, and unpublished data). In addition, the over-
expression of HDAC6-GFP favored the adhesion and trans-
migration of CEM cells under flow conditions, whereas the
rolling and detachment steps were proportionally signifi-
cantly diminished (Figure 7D). Furthermore, the number of
leukocyte–endothelium interactions was dramatically in-
creased in the HDAC6-GFP–transduced cells (absolute val-
ues: 574 for pLZR-HDAC6 vs. 258 for pLZR-GFP or 327 for
untransduced parental cells). These data concur with those
obtained using the chemical HDAC6 inhibitor (Figure 3E). In
conclusion, overexpression of both HDAC6 and the deacety-
lase dead mutant, which localizes at motility-related struc-
tures, enhances lymphocyte migration. Therefore, deacety-
lase activity appears to be dispensable for HDAC6-regulated
chemotaxis.
Knocking Down of HDAC6 Inhibits Lymphocyte
Chemotaxis
The effect of HDAC6 on lymphocyte chemotaxis was also
analyzed by knocking down expression. We found that
siRNA-HDAC6-interfered PBL and CEM cells showed a
diminished expression of HDAC6 and a defective migratory
activity in response to the chemokine SDF-1 (Figure 8,
B–D). To unequivocally demonstrate that HDAC6 molecule
itself was accounting for the above-described functional ef-
fects, HDAC6wt, and catalytically inactive HDAC6DD were
compared in restoring the migration of HDAC6-interfered
cells. The results convincingly show that defective cell mi-
gration is reverted at comparable level by overexpression of
both HDAC6wt and HDAC6DD molecules (Figure 8C) and
that the effect is HDAC6 specific. Moreover, adhesion and
transmigration of HDAC6 knockdown CEM cells to acti-
vated HUVEC was assessed under shear stress conditions.
As observed above for TSA-treated lymphocytes (Figure 3, E
and F), a reduced number of adherent and transmigrated
Figure 5. Niltubacin competes tubacin-mediated effect on
HDAC6 tubulin deacetylase activity. (A) Effect on tubulin acet-
ylation of increasing doses of tubacin or niltubacin. (B and C)
Prevention of the tubacin inhibitory effect on HDAC6 tubulin
deacetylase activity by niltubacin. Western blotting of a repre-
sentative experiment (B) and competition curve of increasing
doses of niltubacin versus 0.5 M tubacin. Mean  SD of four
independent experiments is represented (C). (D) Inhibition of
SDF-1– directed migration by increasing doses of tubacin alone
or 0.5 M tubacin plus increasing doses of niltubacin. In each
paired histograms, the same final amounts of tubacin alone (f) or
Tubacin plus niltubacin () are represented.
Figure 6. TSA, tubacin, and niltubacin do not modify the polar-
ization of PBL induced by SDF-1. PBL were treated as indicated and
then allowed to adhere to FN-coated coverslips for 15 min. Cells
were then fixed and stained with an anti-ICAM-3 mAb followed by
an FITC-labeled secondary antibody. Cell polarization was deter-
mined as stated in Materials and Methods. The arithmetic mean  SD
of three independent experiments is shown.
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lymphocytes was found in HDAC6-knockdown cells (Figure
8D). These data show that the overexpression of HDAC6
enhances lymphocyte migration, whereas its targeting inhib-
its lymphocyte chemotaxis.
Figure 7. Functional effects of HDAC6 overexpression in T-cell migration. (A) CEM cells (1.0 107) transduced or not with GFP or HDAC6-GFP
were lysed, sonicated, and immunoblotted with antibodies against the indicated molecules. (B) HDAC6-GFP overexpression enhanced the
migratory behavior of CEM cells. Transduced CEM cells, overexpressing GFP alone, wtHDAC6-GFP or HDAC6 H216A/H611A-EGFP (HDAC6
DD) were allowed to transmigrate in Transwell chambers toward 100 ng/ml SDF-1. Fold induction  SD of migrated cells of three different
experiments is shown. Quantitative flow cytometric analyses of the expression levels by CEM cells transduced with GFP, HDAC6-GFP, and
HDAC6DD-GFP. (C) Confocal videomicroscopy sequence showing the cellular distribution of GFP, or HDAC6-GFP in CEM cells. Image represents
the fluorescence intensity of GFP in an arbitrary pseudocolor map (bar on top left). (D) HDAC6 enhances lymphocyte transendothelial migration
under flow. Rolling, adhesion, transmigration, and detachment of HDAC6-overexpressing CEM cells under shear stress. Transendothelial
migration of parental and transduced CEM cells (GFP alone or HDAC6-GFP) under shear stress across a TNF-–activated HUVEC monolayer. The
number of rolling (white bars), adhered (light gray tone bars), transmigrated (dark gray bars) and detached (black bars) cells were obtained as
described in Materials and Methods. Data represent values  SD from two independent experiments.
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DISCUSSION
Although the roles of tubulin cytoskeleton and microtubule
acetylation in the migration of adherent cells have been
studied (Joseph et al., 1989; Terzis et al., 1997; Westerlund et
al., 1997; Hubbert et al., 2002; Haggarty et al., 2003), little is
known regarding its involvement in the motility of leuko-
cytes. In this work, we have addressed the possible role of
HDAC6 tubulin deacetylase in the migratory activity of
T-lymphocytes. We have found that activated T-cells show
increased levels of acetylated microtubules around the
MTOC, partially colocalizing with HDAC6. It has been re-
ported that the microtubular network is retracted toward the
uropod in T-cells polarized by chemokines (Ratner et al.,
1997). On the other hand, we and others have previously
shown that microtubules do not play an important role in
uropod formation (Wilkinson, 1986; Campanero et al., 1994;
Brown et al., 2001). Whether the enhanced levels of acety-
lated microtubules seen in polarized migrating T-lympho-
cytes are part of the mechanism by which microtubular
bundles are retracted into the uropod or occur after retrac-
tion of the microtubule meshwork into this structure is still
an open question. However, our data using different chem-
ical inhibitors of HDAC6 and experiments with cells over-
expressing HDAC6 deacetylase dead mutant do not support
a role for tubulin deacetylase activity in the acquisition of a
polarized migratory cell shape.
Our data on the localization of HDAC6 at motile protru-
sive structures, such as the leading edge and the uropod,
support a possible involvement of this molecule in the reg-
ulation of lymphocyte locomotion. Accordingly, we found
that the migration of T-cells in response to chemokines is
reduced by HDAC6 siRNA and increased by HDAC6 over-
expression and that these effects are not due to changes in
cell adhesiveness under static conditions. Nevertheless, our
data under shear stress conditions clearly indicate that ad-
hesion strength is weaker in lymphocytes in which HDAC6
has been targeted by either a chemical inhibitor or specific
siRNA knockdown. Hence, HDAC6 molecules appear to be
required for adhesion and transmigration of lymphocytes
under mechanical stress conditions or when cells transmi-
grate across constricted spaces. These data, together with
similar results in mouse NIH3T3 fibroblasts (Hubbert et al.,
2002), suggest that HDAC6 levels modify molecular inter-
actions or intracellular signaling pathways involved in the
Figure 8. Regulation of the chemotactic and transmigration responses of lymphocytes by silencing of HDAC6. (A) HDAC6-GFP or HDAC6
H216A/H611A-GFP overexpression enhanced the migratory ability of PBLs versus GFP overexpression. Nucleofected PBLs overexpressing
HDAC6-GFP, HDAC6 H216A/H611A (HDAC6 DD), or GFP were allowed to migrate toward a chemotactic gradient of 100 ng/ml SDF-1
in Transwell chambers. Two independent experiments with different healthy donors are shown. (B) Effect of HDAC6 knocking-down in PBL
chemotaxis. Western blotting analysis of HDAC6 and acetylated tubulin in siRNA HDAC6-interfered PBLs. Two independent migration
assays in Transwell chambers, with HDAC6 knocked-down PBLs versus mock nucleofected with control negative oligonucleotides from
different healthy donors, are shown. (C) Rescue of defective migratory activity of HDAC6 knockdown cells. CEM cells were interfered with
siRNA HDAC6, and 48 h later were transfected with either wild type or DD (double deacetylase dead mutant) and then assayed for
chemotactic migration in Transwell chambers. (D) HDAC6 knockdown inhibits lymphocyte transendothelial migration under flow. Rolling,
adhesion, transmigration, and detachment events were quantified for negative control siRNA (dark gray bars) and HDAC6 siRNA (white
bars) treated cells under physiological shear stress on a TNF-–activated HUVEC monolayer. The number of cells in each step was quantified
as described in Material and Methods. Control Western blotting analysis of HDAC6 and alpha-tubulin in siRNA HDAC6-interfered CEM cells
is shown. Data show mean values  SD from four independent experiments.
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modulation of cell motility. Interestingly, we have found
that the levels of HDAC6 but not its deacetylase activity
seems to be critical for lymphocyte chemotaxis. Hence, our
data with a panel of tubacin derivatives, together with the
results with cells overexpressing wt and deacetylase inactive
forms of HDAC6, underscore the critical role of this mole-
cule in lymphocyte motility regardless of its enzymatic ac-
tivity. This is apparently in disagreement with data obtained
in NIH3T3 fibroblasts, in which HDAC6 deacetylase activity
was related to cell motility (Hubbert et al., 2002; Haggarty et
al., 2003; Palazzo et al., 2003). However, it is feasible that
HDAC6 has a scaffold role for the rapid formation of mo-
lecular complexes required for lymphocyte migration, a pro-
cess 10- to 20-fold faster than that of fibroblasts (Serrador et
al., 1999). Hence, very dynamic processes such as leukocyte
locomotion would require a rapid HDAC6-mediated on/off
assembly of molecular complexes, whereas this effect of
HDAC6 would be dispensable in slow dynamic processes
such as fibroblast locomotion or other phenomena involving
cell-to-cell immune or viral-mediated interactions (Serrador
et al., 2004; Valenzuela-Fernandez et al., 2005).
Little is known about the signal transduction pathways
controlling HDAC6 activity. It has been recently described
that HDAC6 forms complexes with phosphatases, including
the catalytic subunit of PP1, and that HDAC6-PP1 interac-
tion is disrupted by TSA (Brush et al., 2004; Chen et al., 2005).
In addition, we have previously reported that tubulin acet-
ylation diminishes in lymphocytes when the activity of
RhoA is abolished (Vicente-Manzanares et al., 2002). Fur-
thermore, it is known that Rho GTPases coordinate the two
poles of migrating T-lymphocytes (Sanchez-Madrid and del
Pozo, 1999; Worthylake and Burridge, 2001) and control the
dynamics of actin and tubulin cytoskeleton (Wittmann and
Waterman-Storer, 2001; Ridley et al., 2003). It is therefore
feasible that HDAC6 has a role in the cross-talk between
tubulin- and actin-associated molecules. This role of HDAC6
might explain the relationship between chemokines, Rho/
mDia activation/inactivation (Vicente-Manzanares et al.,
2002; Palazzo et al., 2004; Destaing et al., 2005) and the
consequences of targeting HDAC6 on cell migration
(Hubbert et al., 2002; Haggarty et al., 2003; and this report).
Whether Rho GTPases could regulate the activity of HDAC6
and its interaction with motor proteins is an interesting
point to be explored. We propose that mechanisms such as
alteration in signaling or relative PP1, HSP90, mDia, dynein,
or tubulin dissociation from molecular complexes with
HDAC6 (Kawaguchi et al., 2003; Brush et al., 2004; Bali et al.,
2005; Destaing et al., 2005; Hideshima et al., 2005; Kovacs et
al., 2005) could modulate lymphocyte migration indepen-
dently of its deacetylase activity.
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